<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00744211</url>
  </required_header>
  <id_info>
    <org_study_id>SURG-001-07F</org_study_id>
    <nct_id>NCT00744211</nct_id>
  </id_info>
  <brief_title>Proteolytic Enzyme Induction Within the Human Myocardial Interstitium</brief_title>
  <official_title>Proteolytic Enzyme Induction Within the Human Myocardial Interstitium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A robust release of endothelin-1-1 (ET) with subsequent ETA subtype receptor (ET-AR)
      activation occurs in patients following cardiac surgery requiring cardiopulmonary bypass
      (CPB). Increased ET-AR activation has been identified in patients with poor left ventricular
      (LV) function (reduced ejection fraction; EF). Accordingly, this study tested the hypothesis
      that a selective ET-AR antagonist (ET-ARA) administered peri-operatively would favorably
      affect post-CPB hemodynamic profiles in patients with a pre-existing poor LVEF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with a reduced LVEF were prospectively randomized, in a blinded fashion, at the time
      of elective coronary revascularization and/or valve replacement requiring CPB, to infusion of
      the highly-selective and potent ET-ARA, sitaxsentan at 1 or 2 mg/kg (IV bolus) or vehicle
      (saline). Infusion of the ET-ARA/vehicle was performed immediately prior to separation from
      CPB and again at 12 hrs post-CPB. ET and hemodynamic measurements were performed at baseline,
      at separation from CPB (Time 0) and at 0.5, 6, 12, 24 hrs post-CPB.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary Vascular Resistance</measure>
    <time_frame>Baseline, 0, 6, 12 and 24 hours post-cardiopulmonary bypass (CPB)</time_frame>
    <description>Pulmonary Vascular Resistance (d.s.cm-5)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Endothelin-1</measure>
    <time_frame>Baseline, 0, 6, 12 and 24 hours post-CPB</time_frame>
    <description>Plasma Endothelin-1 (fmol/mL)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Sitaxsentan Levels</measure>
    <time_frame>0, 6, 12 and 24 hours post-CPB</time_frame>
    <description>Sitaxsentan levels (microg/mL)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Other Adverse Events By Type</measure>
    <time_frame>up to 24-hours post-CPB</time_frame>
    <description>Other (non-serious) Adverse Events (reported by arm/group)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Heart Disease</condition>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ET-ARA 1mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ET-ARA 1 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ET-ARA 2mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ET-ARA 2 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1mg/kg sitaxsentan sodium</intervention_name>
    <description>1mg/kg sitaxsentan sodium (intravenous bolus) performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.</description>
    <arm_group_label>ET-ARA 1mg/kg</arm_group_label>
    <other_name>TBC11251Na</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2mg/kg sitaxsentan sodium</intervention_name>
    <description>2mg/kg sitaxsentan sodium (intravenous bolus) performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.</description>
    <arm_group_label>ET-ARA 2mg/kg</arm_group_label>
    <other_name>TBC11251Na</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Intravenous bolus performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.</description>
    <arm_group_label>Vehicle</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;60 years of age

          -  Body mass index &lt;40 kg/m2

          -  Left ventricular ejection fraction less than or equal to 50% documented by a
             pre-operative echocardiogram

          -  Patients undergoing coronary artery bypass (CABG), aortic and/or mitral valve
             replacement or combined CABG and valve procedures requiring CPB.

          -  If diabetic, be under proper control, (fasting glucose &lt;350 mg/dL or recent hemoglobin
             A1c [HgbA1c] &lt;9%).

          -  If hypertensive, be on a stable medical regimen with no significant changes over the
             past 30 days.

          -  Female of child bearing potential with a negative pregnancy test, or post-menopausal
             for at least 2 years

          -  The patient is an appropriate study candidate as determined by the Investigator on the
             basis of medical history and physical examination

        Exclusion Criteria:

          -  Emergent revascularization

          -  Previous stroke or thrombo-embolic event in the 3 months prior to study entry

          -  A previous myocardial infarction within the last 7 days

          -  Documented coagulopathy

          -  Hepatic dysfunction as defined by aspartate transaminase (AST) or alanine transaminase
             (ALT) &gt; 1.5 times the upper limit of normal

          -  Patient is pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis Spinale, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wm. Jennings Bryan Dorn VA Medical Center, Columbia, SC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ralph H. Johnson VA Medical Center, Charleston, SC</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401-5799</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Spinale FG, Koval CN, Deschamps AM, Stroud RE, Ikonomidis JS. Dynamic changes in matrix metalloprotienase activity within the human myocardial interstitium during myocardial arrest and reperfusion. Circulation. 2008 Sep 30;118(14 Suppl):S16-23. doi: 10.1161/CIRCULATIONAHA.108.786640.</citation>
    <PMID>18824748</PMID>
  </results_reference>
  <results_reference>
    <citation>Ford RL, Mains IM, Hilton EJ, Reeves ST, Stroud RE, Crawford FA Jr, Ikonomidis JS, Spinale FG. Endothelin-A receptor inhibition after cardiopulmonary bypass: cytokines and receptor activation. Ann Thorac Surg. 2008 Nov;86(5):1576-83. doi: 10.1016/j.athoracsur.2008.06.076.</citation>
    <PMID>19049753</PMID>
  </results_reference>
  <results_reference>
    <citation>Toole JM, Ikonomidis JS, Szeto WY, Zellner JL, Mulcahy J, Deardorff RL, Spinale FG. Selective endothelin-1 receptor type A inhibition in subjects undergoing cardiac surgery with preexisting left ventricular dysfunction: Influence on early postoperative hemodynamics. J Thorac Cardiovasc Surg. 2010 Mar;139(3):646-54. doi: 10.1016/j.jtcvs.2009.11.046. Epub 2010 Jan 13.</citation>
    <PMID>20074751</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2008</study_first_submitted>
  <study_first_submitted_qc>August 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2008</study_first_posted>
  <results_first_submitted>November 7, 2014</results_first_submitted>
  <results_first_submitted_qc>November 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 9, 2017</results_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitaxsentan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Prospective randomization in a blinded fashion, at the time of elective coronary revascularization or valve replacement requiring cardiopulmonary bypass.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Vehicle</title>
          <description>Saline intravenous bolus</description>
        </group>
        <group group_id="P2">
          <title>ET-ARA 1mg/kg</title>
          <description>1mg/kg sitaxsentan sodium intravenous bolus</description>
        </group>
        <group group_id="P3">
          <title>ET-ARA 2mg/kg</title>
          <description>2mg/kg sitaxsentan sodium intravenous bolus</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Baseline</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>0.5 Hours After Cardiopulmonary Bypass</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>6 Hours After Cardiopulmonary Bypass</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>12 Hours After Cardiopulmonary Bypass</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>24 Hours After Cardiopulmonary Bypass</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vehicle</title>
          <description>Saline, intravenous bolus</description>
        </group>
        <group group_id="B2">
          <title>ET-ARA 1mg/kg</title>
          <description>1mg/kg sitaxsentan sodium</description>
        </group>
        <group group_id="B3">
          <title>ET-ARA 2mg/kg</title>
          <description>2mg/kg sitaxsentan sodium</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" spread="2"/>
                    <measurement group_id="B2" value="62" spread="3"/>
                    <measurement group_id="B3" value="68" spread="3"/>
                    <measurement group_id="B4" value="66" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left Ventricular Ejection Fraction (LVEF)</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" spread="3"/>
                    <measurement group_id="B2" value="38" spread="2"/>
                    <measurement group_id="B3" value="37" spread="3"/>
                    <measurement group_id="B4" value="37" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma Endothelin</title>
          <units>fmol/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.9" spread="0.4"/>
                    <measurement group_id="B2" value="3.7" spread="0.3"/>
                    <measurement group_id="B3" value="4.3" spread="0.7"/>
                    <measurement group_id="B4" value="4.0" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systemic vascular resistance</title>
          <units>dyne*second/centimeter˄5</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1408" spread="119"/>
                    <measurement group_id="B2" value="1359" spread="210"/>
                    <measurement group_id="B3" value="1307" spread="112"/>
                    <measurement group_id="B4" value="1358" spread="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pulmonary vascular resistance</title>
          <units>dyne*second/centimeter˄5</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="153.8" spread="19.9"/>
                    <measurement group_id="B2" value="213.0" spread="65.3"/>
                    <measurement group_id="B3" value="174.6" spread="28.4"/>
                    <measurement group_id="B4" value="180" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pulmonary Vascular Resistance</title>
        <description>Pulmonary Vascular Resistance (d.s.cm-5)</description>
        <time_frame>Baseline, 0, 6, 12 and 24 hours post-cardiopulmonary bypass (CPB)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vehicle</title>
            <description>Vehicle group</description>
          </group>
          <group group_id="O2">
            <title>1mg/kg ET-ARA</title>
            <description>1 mg/kg ET-ARA</description>
          </group>
          <group group_id="O3">
            <title>2mg/kg ET-ARA</title>
            <description>2 mg/kg ET-ARA</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Vascular Resistance</title>
          <description>Pulmonary Vascular Resistance (d.s.cm-5)</description>
          <units>dyne*second/centimeter˄5</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.8" spread="19.9"/>
                    <measurement group_id="O2" value="213.0" spread="65.3"/>
                    <measurement group_id="O3" value="174.6" spread="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 hours post-CPB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.5" spread="20.7"/>
                    <measurement group_id="O2" value="125.3" spread="24.8"/>
                    <measurement group_id="O3" value="175.8" spread="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours post-CPB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.7" spread="28.0"/>
                    <measurement group_id="O2" value="144.6" spread="15.2"/>
                    <measurement group_id="O3" value="132.7" spread="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours post-CPB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146.8" spread="21.6"/>
                    <measurement group_id="O2" value="132.7" spread="12.7"/>
                    <measurement group_id="O3" value="136.6" spread="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours post-CPB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.3" spread="26.6"/>
                    <measurement group_id="O2" value="125.5" spread="22.3"/>
                    <measurement group_id="O3" value="138.7" spread="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>p&lt;0.05; Pairwise tests of individual groups means were compared by adjusted probabilities (Bonferroni method).</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Endothelin-1</title>
        <description>Plasma Endothelin-1 (fmol/mL)</description>
        <time_frame>Baseline, 0, 6, 12 and 24 hours post-CPB</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vehicle</title>
            <description>Vehicle Group</description>
          </group>
          <group group_id="O2">
            <title>1mg/kg ET-ARA</title>
            <description>1 mg/kg ET-ARA</description>
          </group>
          <group group_id="O3">
            <title>2mg/kg ET-ARA</title>
            <description>2 mg/kg ET-ARA</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Endothelin-1</title>
          <description>Plasma Endothelin-1 (fmol/mL)</description>
          <units>fmol/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="0.4"/>
                    <measurement group_id="O2" value="3.7" spread="0.3"/>
                    <measurement group_id="O3" value="4.3" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 hours post-CPB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="0.8"/>
                    <measurement group_id="O2" value="4.7" spread="0.5"/>
                    <measurement group_id="O3" value="4.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours post-CPB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="1.1"/>
                    <measurement group_id="O2" value="7.2" spread="1.3"/>
                    <measurement group_id="O3" value="7.6" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours post-CPB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="1.1"/>
                    <measurement group_id="O2" value="8.8" spread="1.7"/>
                    <measurement group_id="O3" value="10.4" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours post-CPB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="1.0"/>
                    <measurement group_id="O2" value="8.3" spread="1.0"/>
                    <measurement group_id="O3" value="8.6" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>Pairwise tests of individual groups means were compared by adjusted probabilities (Bonferroni method).</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Sitaxsentan Levels</title>
        <description>Sitaxsentan levels (microg/mL)</description>
        <time_frame>0, 6, 12 and 24 hours post-CPB</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1mg/kg ET-ARA</title>
            <description>1 mg/kg ET-ARA</description>
          </group>
          <group group_id="O2">
            <title>2mg/kg ET-ARA</title>
            <description>2 mg/kg ET-ARA</description>
          </group>
        </group_list>
        <measure>
          <title>Sitaxsentan Levels</title>
          <description>Sitaxsentan levels (microg/mL)</description>
          <units>microg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 hours post-CPB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.35" spread="0.83"/>
                    <measurement group_id="O2" value="11.78" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours post-CPB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.01"/>
                    <measurement group_id="O2" value="2.24" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours post-CPB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="1.26"/>
                    <measurement group_id="O2" value="8.63" spread="3.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours post-CPB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.01"/>
                    <measurement group_id="O2" value="0.09" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Other Adverse Events By Type</title>
        <description>Other (non-serious) Adverse Events (reported by arm/group)</description>
        <time_frame>up to 24-hours post-CPB</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vehicle</title>
            <description>Vehicle group</description>
          </group>
          <group group_id="O2">
            <title>1mg/kg ET-ARA</title>
            <description>1 mg/kg ET-ARA</description>
          </group>
          <group group_id="O3">
            <title>2mg/kg ET-ARA</title>
            <description>2 mg/kg ET-ARA</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Other Adverse Events By Type</title>
          <description>Other (non-serious) Adverse Events (reported by arm/group)</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cardiovascular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurological</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genitourinary/Gynecological</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endocrine/Metabolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunological/Allergic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematological/Lymphatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychological/Behavioral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HEENT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dermatological</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Chi-square tests for differences between groups.</non_inferiority_desc>
            <p_value>0.015</p_value>
            <p_value_desc>P-value is associated with the hematological/lymphatic adverse event.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Post-operative period, reported up to 30+ days post CPB</time_frame>
      <desc>Data for the Number of Participants Affected with Other Adverse Events is no longer available. Other Adverse Event Data is only available as a count of occurrences of AE's by Arm/Group.</desc>
      <group_list>
        <group group_id="E1">
          <title>Vehicle</title>
          <description>Vehicle Group</description>
        </group>
        <group group_id="E2">
          <title>ET-ARA 1mg/kg</title>
          <description>ET - ARA 1 mg / kg</description>
        </group>
        <group group_id="E3">
          <title>ET-ARA 2mg/kg</title>
          <description>ET - ARA 2 mg / kg</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombo-embolic event</sub_title>
                <description>When all SAE's were considered as a composite, there were no significant differences between treatment groups (Chi-square 1.59; p=0.452).</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Following adjudication, all 3 deaths were determined to be unrelated to ET-ARA treatment.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal (ischemic bowel)</sub_title>
                <description>When all SAE's were considered as a composite, there were no significant differences between treatment groups (Chi-square 1.59; p=0.452).</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pulmonary/infection</sub_title>
                <description>When all SAE's were considered as a composite, there were no significant differences between treatment groups (Chi-square 1.59; p=0.452).</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size, which in turn can result in a disproportionate number of patients with greater pre-operative risk profiles randomized to one treatment group.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Francis G. Spinale</name_or_title>
      <organization>University of South Carolina SOM</organization>
      <phone>803-777-3964</phone>
      <email>cvctrc@uscmed.sc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

